Heron Therapeuti Market Cap ($53.89 Million)
Market Cap & Net Worth: Heron Therapeuti (HRTX)
Heron Therapeuti market cap. Heron Therapeuti (NASDAQ:HRTX) has a market capitalization of $53.89 Million ($53.89 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21419 globally and #4812 in its home market, demonstrating a -5.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Heron Therapeuti's stock price $0.28 by its total outstanding shares 189279369 (189.28 Million). Also see Heron Therapeuti (HRTX) cash flow conversion for how efficiently the company converts equity into cash flow.
Heron Therapeuti Market Cap History (2015–2026)
Heron Therapeuti market cap history from 2015 to 2026. Data shows change from $5.05 Billion to $53.89 Million (-32.68% CAGR). Check HRTX share price today for real-time trading data and today's change.
Index Memberships
Heron Therapeuti is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #611 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2036 of 3165 |
Weight: Heron Therapeuti's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Heron Therapeuti Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Heron Therapeuti's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Heron Therapeuti (HRTX) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.59x
Heron Therapeuti's market cap is 1.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.48 Billion | $1.28 Million | -$173.14 Million | 1938.67x | N/A |
| 2017 | $3.43 Billion | $30.77 Million | -$197.48 Million | 111.35x | N/A |
| 2018 | $4.91 Billion | $77.47 Million | -$178.84 Million | 63.37x | N/A |
| 2019 | $4.45 Billion | $145.97 Million | -$204.75 Million | 30.47x | N/A |
| 2020 | $4.01 Billion | $88.64 Million | -$224.43 Million | 45.20x | N/A |
| 2021 | $1.73 Billion | $86.35 Million | -$217.66 Million | 20.01x | N/A |
| 2022 | $473.20 Million | $107.67 Million | -$134.52 Million | 4.39x | N/A |
| 2023 | $321.77 Million | $127.04 Million | -$110.56 Million | 2.53x | N/A |
| 2024 | $289.60 Million | $144.28 Million | -$13.58 Million | 2.01x | N/A |
| 2025 | $246.06 Million | $154.90 Million | -$20.20 Million | 1.59x | N/A |
Competitor Companies of HRTX by Market Capitalization
Companies near Heron Therapeuti in the global market cap rankings as of November 4, 2026. Also see HRTX total assets for a full breakdown of the balance sheet.
Key companies related to Heron Therapeuti by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Heron Therapeuti (2015–2026)
Market capitalization of Heron Therapeuti from 2015 to today. Between 2015 and today, Heron Therapeuti's market cap moved from $5.05 Billion to $ 53.89 Million, with a yearly change of -32.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $53.89 Million | -78.10% |
| 2025 | $246.06 Million | -15.03% |
| 2024 | $289.60 Million | -10.00% |
| 2023 | $321.77 Million | -32.00% |
| 2022 | $473.20 Million | -72.62% |
| 2021 | $1.73 Billion | -56.86% |
| 2020 | $4.01 Billion | -9.94% |
| 2019 | $4.45 Billion | -9.41% |
| 2018 | $4.91 Billion | +43.31% |
| 2017 | $3.43 Billion | +38.17% |
| 2016 | $2.48 Billion | -50.94% |
| 2015 | $5.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Heron Therapeuti was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.89 Million USD |
| MoneyControl | $53.89 Million USD |
| MarketWatch | $53.89 Million USD |
| marketcap.company | $53.89 Million USD |
| Reuters | $53.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more